Our top pick for
Building a portfolio
AlloVir, Inc is a biotechnology business based in the US. AlloVir shares (ALVR) are listed on the NASDAQ and all prices are listed in US Dollars. AlloVir employs 32 staff and has a market cap (total outstanding shares value) of USD$2.6 billion.
|Latest market close||USD$45.5|
|52-week range||USD$18.15 - USD$48.96|
|50-day moving average||USD$41.5139|
|200-day moving average||USD$32.8731|
|Wall St. target price||USD$46.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||0.57%|
|1 month (2020-12-23)||-2.53%|
|3 months (2020-10-23)||76.29%|
|6 months (2020-07-20)||N/A|
|1 year (2020-01-20)||N/A|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
|Gross profit TTM||USD$165,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
There are currently 2.5 million AlloVir shares held short by investors – that's known as AlloVir's "short interest". This figure is 112.7% up from 1.2 million last month.
There are a few different ways that this level of interest in shorting AlloVir shares can be evaluated.
AlloVir's "short interest ratio" (SIR) is the quantity of AlloVir shares currently shorted divided by the average quantity of AlloVir shares traded daily (recently around 353598.47434119). AlloVir's SIR currently stands at 7.21. In other words for every 100,000 AlloVir shares traded daily on the market, roughly 7210 shares are currently held short.
However AlloVir's short interest can also be evaluated against the total number of AlloVir shares, or, against the total number of tradable AlloVir shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AlloVir's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AlloVir shares in existence, roughly 40 shares are currently held short) or 0.0899% of the tradable shares (for every 100,000 tradable AlloVir shares, roughly 90 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AlloVir.
Find out more about how you can short AlloVir stock.
We're not expecting AlloVir to pay a dividend over the next 12 months.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.